Driven by its vision of becoming a leading global generics organization, Glenmark Generics Ltd. (GGL) has structured its businesses as US Generics, European Generics, the Active Pharmaceutical Ingredient (API) business and the Oncology Business. A subsidiary of Glenmark Pharmaceuticals Limited, GGL focuses on developing, manufacturing, selling and the distribution of generics through wholesalers, retailers and pharmacy chains. From APIs to front end marketing capabilities, GGL’s businesses are vertically integrated into the generics market, by focusing on key niche segments including Dermatology, Hormones, Controlled Substances, Oncology and Modified Release Products.
Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations. How did you become part of Glenmark,…
“Argentina’s health system is in agony” In March 2002, amidst an economic crisis and national healthcare emergency the then Minister of Health Gines Gonzales Garcia declared “Argentina’s health system is…
Santiago Garcia Belmonte, president of Biosidus, discusses how global regulatory trends are driving change in the Argentinian biotech industry, as well the new direction his firm has taken over the…
The Executive Director of Argentina’s social security health provider, PAMI, discusses the institutions mission and evolution, as well as his hopes for the future of the Argentinian health system. What…
Francisco Molinari, CEO of Argentina’s most sophisticated biotech group discusses Argentina’s competitiveness in the global biosimilar market, the current constraints limiting innovation in Argentina, and his company’s recent transition from…
Medtronic’s Regional Director for the South Cone shares with us the story of the company’s impressive success since the rebirth of their Argentinian affiliate in 2007, and indicates that Argentinian…
The national coordinator for Argentina’s ministry of health Plan Remediar discusses developing a professional management culture in the country’s public health centers, and the programs wider role in the public…
Dräger’s Sub Regional manager discusses the challenges of dealing with the fragmented and diverse Argentine healthcare sector, and some of the various strategies and approaches the firm uses to succeed…
The COO of Argentina’s largest logistics provider explains how the firm evolved into the preeminent player in the pharmaceutical logistics market, transporting roughly half of all pharmaceutical and medical device…
Alicia Alvarez Berkenwald, Partner at the specialized intellectual property services firm Berken IP, gives an introduction to the Argentinian IP environment, common strategies used to bypass obstacles, and Berken IP’s…
The vice president of Laboratorio Tuteur highlights the position of his company as the leaders in specialty products in Argentina. Could you please give us an historical overview of Laboratorio…
Founder of Promedon Marcelo Olmedo discusses innovation in Cordoba, and the birth and success of Promedon, a flagship company of the region. How do you see the importance of…
Chagas disease, caused by the protozoan parasite Trypanosoma cruzi, is a potentially life-threatening illness currently afflicting eight to ten million people worldwide. Latin America is home to the vast majority…
See our Cookie Privacy Policy Here
